Connecticut Attorney General William Tong is urging residents to review their prescription history and file a claim for possible compensation. The state has secured a $96 million settlement with several generic drug manufacturers accused of colluding to inflate prices on essential medicines.
What drugs are covered?
The settlement covers dozens of generic products, including specific formulations of albuterol inhalers, prednisone tablets, and warfarin sodium. Other medications are listed in the full settlement document, which is available on the AG’s website.
Who is paying?
Payments will come from the following manufacturers: Glenmark, Lannett, Bausch, Apotex, Heritage and Heritage’s parent company, Emcure. The settlement agreement requires these companies to provide restitution to eligible Connecticut consumers.
How to claim compensation
Consumers can submit a claim online at AGGenericDrugs.com. Additional assistance is available by calling 1‑866‑290‑0182 or emailing [email protected]. The AG’s office advises claimants to have their prescription records handy, including the name of the medication, the date of purchase and the pharmacy where it was filled.
Attorney General’s statement
“Major players across the generic drug industry rigged the market and forced customers to pay higher prices for critical medication,” Tong said in a statement. “Our settlements have secured tens of millions of dollars in restitution, and we are just getting started.”
Why this matters
The settlement represents a significant win for Connecticut consumers who have been overcharged for everyday medicines. By holding manufacturers accountable, the AG’s office aims to deter future price‑fixing schemes and protect families from unnecessary financial burdens.
Next steps for residents
Eligible individuals should act promptly, as claim deadlines will be set by the settlement administrators. The AG’s office will continue to monitor the situation and pursue additional actions if further wrongdoing is uncovered.
Original reporting: NBC Connecticut — read the source article.
